Teva Pharmaceutical Industries Ltd. said Thursday the Food and Drug Administration approved its generic version of GlaxoSmithKline's heart drug Coreg.

The Israeli generic drugmaker company received approval for tablets of carvedilol in 3.125-milligram, 6.25-milligram, 12.5-milligram, and 25-milligram doses. The drug is aimed at treating left ventricular dysfunction following a heart attack and for hypertension.

Generic drug developer Mylan Laboratories Inc. also received approval for a version Thursday and Caraco Pharmaceutical Laboratories Ltd. received approval for generic Coreg Wednesday.